Payment overview · 2025
General Payments
$696.90
34 reported records · 9 companies
Healthcare provider profile · identity verified
Narcisa E Murillo, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CLIFTON, NJ · NPI 1942282306
Verified facts
What the public records show
CMS Open Payments records show Narcisa E Murillo, M.D. received $696.90 in general payments during 2025 across 34 reported records.
AstraZeneca Pharmaceuticals LP accounted for 38.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Linzess, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 242 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 376 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $266.65 | 38.3% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $112.69 | 16.2% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $83.69 | 12.0% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $69.20 | 9.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $63.82 | 9.2% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.33 | 8.2% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $15.94 | 2.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.07 | 2.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.51 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $696.90 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $220.14 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $199.47 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $152.96 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $112.69 | 7 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $66.84 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $63.82 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.33 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $36.54 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $33.82 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 242 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 376 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 41 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | 19 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
55 | 37 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
242 | 52 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
376 | 76 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 516 | 156 |
| Jardiance | Empagliflozin | 376 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 303 | 80 |
| Gabapentin | Gabapentin | 299 | 103 |
| Metformin Hcl | Metformin Hcl | 297 | 88 |
| Farxiga | Dapagliflozin Propanediol | 242 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 228 | 53 |
| Omeprazole | Omeprazole | 217 | 70 |
| Losartan Potassium | Losartan Potassium | 213 | 59 |
| Glimepiride | Glimepiride | 200 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 63 |
| Diclofenac Sodium | Diclofenac Sodium | 191 | 82 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 178 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 170 | 49 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 170 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 167 | 56 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 164 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 140 | 42 |
| Vascepa | Icosapent Ethyl | 123 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 43 |
| Alendronate Sodium | Alendronate Sodium | 111 | 41 |
| Azithromycin | Azithromycin | 102 | 79 |
| Simvastatin | Simvastatin | 94 | 30 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 94 | 43 |
| Ozempic | Semaglutide | 93 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 92 | 24 |
| Valsartan | Valsartan | 83 | 26 |
| Meclizine Hcl | Meclizine Hcl | 81 | 30 |
| Eliquis | Apixaban | 80 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 29 |
| Memantine Hcl | Memantine Hcl | 66 | 23 |
| Promethazine Hcl | Promethazine Hcl | 65 | 43 |
| Montelukast Sodium | Montelukast Sodium | 62 | 23 |
| Meloxicam | Meloxicam | 61 | 35 |
| Ramipril | Ramipril | 61 | 22 |
| Carvedilol | Carvedilol | 58 | 16 |
| Furosemide | Furosemide | 57 | 19 |
| Prolia | Denosumab | 55 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 25 |
| Memantine Hcl Er | Memantine Hcl | 53 | 19 |
| Myrbetriq | Mirabegron | 52 | 15 |
| Glipizide | Glipizide | 51 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 51 | suppressed |
| Allopurinol | Allopurinol | 50 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 47 | 18 |
| Baclofen | Baclofen | 45 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 38 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 30 |
| Entresto | Sacubitril/Valsartan | 41 | suppressed |
| Linzess | Linaclotide | 41 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 18 |
| Ketoconazole | Ketoconazole | 36 | 17 |
| Sertraline Hcl | Sertraline Hcl | 36 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 28 |
| Ezetimibe | Ezetimibe | 34 | 18 |
| Famotidine | Famotidine | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 27 | 15 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 27 | 23 |
| Donepezil Hcl | Donepezil Hcl | 26 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Prednisone | Prednisone | 22 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | 12 |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 16 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Fluconazole | Fluconazole | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $696.90 · 34 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CREON, FARXIGA, GVOKE HYPOPEN, JARDIANCE, LAGEVRIO, LINZESS, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, Tymlos, VERQUVO, VRAYLAR | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error